Menu
About Us
Company Overview
Corporate Culture
Manufacturing Base
MAH
Drug Development to Commercialization
Milestones
Code of Business Ethics
Services
Services
Providing reliable CDMO solutions with excellent quality and professional services
ADC Platform
Overview
ADC R&D Service Platform
Conjugation Process
Development
and Optimization
Drug Product
Formulation and
Lyophilization Process
Analysis Services
Antibody Manufacturing
ADC Drug Substance
Manufacturing
Lyophilized Drug
Product Manufacture
Protein/Antibody Platform
Overview
Cell Culture
Process Development
Purification Process
Development
Drug Product
Formulation and
Lophilization Process
Analysis Services
GMP Manufacturing
Overview
Drug Substance
Manufacturing
Drug Product
Manufacturing
Process Characterization
/Process Validation
Technology Transfer
Overview
Technology Transfer
Quality
Overview
Quality Control
Quality Assurance
Regulatory Affairs
Overview
Service and Advantages
Investor Relations
Company Profile
Corporate Governance
Announcements and Circulars
The Listed Files
Financial Reports and ESG Reports
Company Promotion Materials
Investor Relations Query
Investor Relations Journal
News & Events
News
Events
Media Attention
Partner News
Resources
Technical Articles
Download Center
Join Us
Members of TOT
Join in TOT
Contact Us
EN
繁體
简体
EN
繁體
简体
Home
<
News&Events
<
News
ADC药物研发的挑战和策略
Date Time:2022-05-31
日期:2022年5月31日
形式:线上直播
5月31日,东曜药业黄鹏博士,携手博瑞医药黄仰青博士以及普方生物刘海东博士,做客同写意直播间,共同探讨《ADC药物研发的挑战和策略》。
上一篇:
第六届中国生物医药创新合作大会
下一篇:
2022新型生物药先进技术峰会
微信
领英
复制链接
The module is under construction